Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer
Clinical Pharmacology & Therapeutics · 09.09.2026
DOI: 10.1002/cpt.70466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 09.09.2026. Verfasst von Vaishali L Chudasama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, New York, New York, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose of enfortumab vedotin 1.25 mg/kg (on days 1 and 8 of a 21‐day dosing cycle) plus pembrolizumab (recommended dosage) and had evaluable pharmacokinetics in the EV‐103 ( N = 121) and EV‐302 ( N = 432) studies. Overall, most patients were older (median age of 69 years), White (74%), and male (77%), with median body weight in EV‐103 (79 kg) trending higher than that in EV‐302 (75 kg). Higher exposures of enfortumab vedotin were associated with consistently higher objective response rates across all exposure quartiles in both studies, and longer survival than chemotherapy in EV‐302. Increased and faster incidence of treatment‐related adverse events (Grade ≥ 3 hyperglycemia, Grade ≥ 3 skin reactions, and Grade ≥ 2 peripheral neuropathy) was also observed with increased exposures. However, dose modifications were effective in managing most adverse events, with most patients having at least partial resolution (hyperglycemia, >75%; skin reactions, >85%; and peripheral neuropathy, >50%). Responses attained with higher early cycle exposure were not impacted by subsequent dose modifications. Overall, exposure–response analysis supports the use of enfortumab vedotin at a starting dose of 1.25 mg/kg and in combination with pembrolizumab for first‐line treatment of locally advanced or metastatic urothelial cancer.
Autor:innen und Institutionen
- Pfizer Inc, New York, New York, USA.
- QuanTx Consulting, Mountain View, California, USA.
- Astellas Pharma, Northbrook, Illinois, USA.
- BeOne Medicines, San Carlos, California, USA.
ORCID-Profile: Vaishali L Chudasama, Hossam Kadry, Daping Zhang, Amit Garg, Yen Lin Chia
Zitieren
APA
Chudasama, V. L., Kastrissios, H., Kadry, H., Zhang, D., Hamed, S., Poondru, S., Bhattacharya, S., Wada, R., Garg, A., & Chia, Y. L. (2026). Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70466
Vancouver
Chudasama VL, Kastrissios H, Kadry H, Zhang D, Hamed S, Poondru S, et al. Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70466
BibTeX
@article{Chudasama2026,
author = {Chudasama, Vaishali L and Kastrissios, Helen and Kadry, Hossam and Zhang, Daping and Hamed, Salaheldin and Poondru, Srinivasu and Bhattacharya, Souvik and Wada, Russ and Garg, Amit and Chia, Yen Lin},
title = {Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70466}
}
EUVIMED